The Monoclonal Pursuit of the Next CMV Therapeutic

There is no doubt that immunity to human cytomegalovirus (CMV) is both cell-and antibody-mediated. Studies in transplant patients showed that absence of T-cell protection with chemotherapy is a set-up for recurrent and severe CMV disease. It was also shown that patients Continue reading The Monoclonal Pursuit of the Next CMV Therapeutic

Antibiotic Inhalers Galore (Part 1):  More Combinations and Permutations than a Rubik’s Cube

There is much interest in inhaled antibiotics these days.  Prima facie, the logic for this approach is compelling: Getting the antibiotic (and a lot of it) directly to the site of infection, while avoiding systemic toxicity, sounds like optimized efficacy Continue reading Antibiotic Inhalers Galore (Part 1):  More Combinations and Permutations than a Rubik’s Cube

Prospecting for New Antibiotics

The QIDP designation was introduced in 2012 to incentivize drug development in antiinfectives. QIDP came with several attractive features, such as prolongation of patent life, FDA expedited review and more.  In addition, FDA made it quite easy to garner the label.  Continue reading Prospecting for New Antibiotics

Quo Vadis, CDI Drugs?

There are only 3 CDI drugs in wider clinical use: vancomycin, metronidazole, and fidaxomicin. They are from totally different classes and have almost nothing in common except for proven efficacy in C. difficile infection (CDI). Like vancomycin, the entire group Continue reading Quo Vadis, CDI Drugs?

Recent Sepsis Literature

SIRS, sepsis, severe sepsis, septic shock is a continuum, a crescendo of signs and symptoms associated with an infection uncontrolled by host responses. An avalanche or cascade of seemingly unstoppable events occurs often in a matter of hours which has Continue reading Recent Sepsis Literature

Polyphor POL7080 And The Journey to The Land of Pyocyanea  (Part 1)

When Roche inlicensed Polyphor’s anti-pseudomonas drug POL7080 in November 2013, it marked a turning point.  It seemed that Big Pharma that had all but abandoned the field in the last decade and was getting engaged in anti-infectives again.  When a Continue reading Polyphor POL7080 And The Journey to The Land of Pyocyanea  (Part 1)

Streptomyces – The Industrious Antibiotic Producer

Like other actinomycetes, the Streptomyces group of microbes straddles the somewhat artificial boundary between bacteria and fungi. Growth on culture plates looks ‘fungal’ and the organism produces spores and germtubes that look like mycelia.  Nonetheless these soil organisms are bacteria and of Continue reading Streptomyces – The Industrious Antibiotic Producer

Aerosolized Antibiotics & Selling Nebulizers

“The medicine comes for free, just pay us for the inhaler” should be the marketing slogan for this group of therapeutics.  Nebulizers are good business: hard to copy as a delivery system, they are a great opportunity to ‘evergreen’ off-patent Continue reading Aerosolized Antibiotics & Selling Nebulizers

It’s Not a Free-Enterprise Market, Stupid!

The economics of developing antibacterials is a frustrating topic to address.  There are unique aspects to the antibiotic market which sets it apart from other medicines, esp. the unique societal aspects of antibiotic use which go beyond the benefit to Continue reading It’s Not a Free-Enterprise Market, Stupid!

Following The Publication Trail of Two RSV Drugs

In a publication from 2007, investigators from Arrow Pharmaceuticals told us that A-60444 (later renamed to RSV-604) was already in Phase 2.  Since then, it has been very quiet about this compound.  Some have suggested that Novartis has stopped development [1], Continue reading Following The Publication Trail of Two RSV Drugs

Bacterial Vaccine Targets

A recent publication [1] from the team which brought us the Meningococcal B vaccine is of interest from the perspective of vaccine development strategy and feasibility.  Link to this post!

Fighting P. aeruginosa (Part II)

At a still earlier stage of development, we found some exciting anti-pseudomonal compounds. First, there is BAL-30072, a sulfactam-derivative.  It has an interesting dual MoA as it works not only as a traditional B-lactam but also as an Fe-chelator blocking bacteria from Continue reading Fighting P. aeruginosa (Part II)

Fighting P. aeruginosa (Part I)

It has never been easy to cure Pseudomonas aeruginosa infections.  Few antibiotics nowadays have reliable activity against this problem pathogen that seems to have more built-in resistance features than most other Gram-negatives.  In the past, cephalosporins, aztreonam, penems, ciprofloxacin, and Continue reading Fighting P. aeruginosa (Part I)